Vipergen EPO Patent Maintained Following Opposition

Vipergen ApS is pleased to announce that European patent EP3914704B1, covering Vipergen’s proprietary cellular Binder Trap Enrichment (cBTE) technology, has been maintained as granted following the EPO Opposition Oral Proceedings held on May 19, 2026. The European Patent Office (EPO) rejected the opposition filed by Amgen/Nuevolution A/S.

The cBTE technology enables small molecule DEL screening to be performed directly inside a living cell, eliminating the need for purified protein and providing physiologically relevant conditions. This opens new possibilities for targeting previously intractable proteins such as transcription factors and intrinsically disordered proteins.

“This is an important outcome for Vipergen and a strong validation of the novelty and inventiveness of our cBTE technology,” said CEO Nils Hansen, PhD at Vipergen. “We are confident in the strength of our intellectual property portfolio and remain fully committed to advancing cell-based DEL screening as a platform for next-generation drug discovery.”

The maintained patent strengthens Vipergen’s intellectual property position and underlines its status as the first and only company capable of screening DELs inside a living cell.

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the USA, EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit https://www.vipergen.com.

For additional information please contact:

Vipergen ApS
info@vipergen.com